Drug trial aims to stop COVID's lasting lung damage
NCT ID NCT04948203
Summary
This study is testing whether the drug sirolimus can prevent permanent lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. Hospitalized patients will be randomly assigned to receive different doses of sirolimus or standard care alone. Researchers will use CT scans at 12 weeks to see if the drug reduces lung scarring compared to usual treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.